# Kids as young as 6 tested in new Wegovy weight loss trial — and there was a troubling side effect

- URL: https://talkfuse.com/story/kids-as-young-as-6-tested-in-new-wegovy-weight-loss-trial-and-there-was-a-troubling-side-effect/
- Published: 2026-11-18T19:01:43+00:00
- Updated: 2026-11-18T19:24:28+00:00
- Original publisher: New York Post (publisher lean: Right)
- Original article: https://nypost.com/2026/11/18/health/kids-as-young-as-6-lost-weight-on-glp-1s-with-new-side-effect/
- Topics: World

## Key points

- Semaglutide reduced BMI in children aged 6 to 11.
- Children taking it grew 1.3 inches less over two years.
- Doctors say the possible effect on adult height needs study.

## Summary

A trial by Wegovy maker Novo Nordisk found that children aged 6 to 11 with obesity lost substantial weight while taking semaglutide. The results could support a request for US approval for this age group in 2027, but the children also grew less during the study, raising questions about possible effects on adult height.

Children received weekly semaglutide or a placebo for two years, alongside diet and exercise counselling. After 18 months, 79% of those taking semaglutide had moved to a lower BMI category and 38% were no longer classed as obese; after two years, their BMI had fallen by 9.4%, while the placebo group’s rose by 8.4%. The semaglutide group grew 1.3 inches less, against typical growth of 4 to 5 inches over two years, and most participants reported side effects, commonly nausea or vomiting. Doctors said longer-term follow-up is needed to understand the growth finding.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
